Vitex.

Both entries are Vitex agnus-castus fruit preparations. Listing both counts one botanical twice rather than adding a partner.

The berry preparation is the standard part used and carries the same diterpene and flavonoid profile. It is one ingredient under two names.

Agnuside is the iridoid glycoside most extracts are standardised to. It is a component of vitex, not a separate botanical.

B6 as pyridoxal-5-phosphate is the cofactor for the decarboxylase that makes dopamine, and dopamine at D2 receptors is the main route through which vitex influences prolactin release. The two act on the same lever from different sides.

Magnesium supports smooth muscle relaxation and works with B6 in neurotransmitter synthesis. It is a standard companion in monthly-cycle formulas built around vitex.

GLA from evening primrose feeds series-1 prostaglandin production, a lipid route entirely separate from the dopaminergic action of vitex. The two are combined for that reason.

Dong quai contributes ferulic acid and coumarin constituents acting on smooth muscle and circulation, while vitex acts centrally on prolactin signalling. They are long paired in women's formulas.

Black cohosh acts on serotonergic and other central receptors rather than on prolactin, so the two cover different parts of midlife hormonal change. Common in combination products.

Mucuna supplies L-dopa, the direct precursor to dopamine, while vitex constituents act as dopamine D2 receptor agonists. Both push prolactin regulation the same way, so the effect adds.

The two are routinely combined for monthly mood support, but St John's wort strongly induces CYP3A4 and P-glycoprotein, which changes how other compounds in the formula are cleared.

Red clover isoflavones bind oestrogen receptors weakly at the tissue level, whereas vitex acts centrally on prolactin release. The routes are distinct rather than duplicated.

Chamomile carries apigenin, which binds the benzodiazepine site of the GABA-A receptor, and it has a long record in preparations aimed at cyclical discomfort and restlessness. Vitex acts on a different axis, the dopaminergic control of pituitary prolactin release. Formulas combine them for that separation of targets rather than because a trial tested the pair.

Melissa officinalis inhibits GABA transaminase in vitro, which is the usual explanation for its calming reputation. Vitex works upstream on hypothalamic and pituitary signalling. The pairing is convention in cycle-support blends, without combination data.

Valerian's valerenic acid modulates the GABA-A receptor and the root is used for sleep onset. Where a formula pairs it with vitex, the sedative effect is valerian's and it can add to other sedating ingredients in the same product. The combination has not been tested as a unit.

Calcium intake has been examined in relation to cyclical physical and mood symptoms in women, with trials of supplemental calcium reporting changes in symptom scores. Symptom scores are self-reported measures, not physiological outcomes. Vitex acts through prolactin signalling, so the two rationales do not overlap.

Alpha-tocopherol has been used for many years in preparations aimed at cyclical breast tenderness, which is also the complaint vitex is most associated with. The two arrive at that use from unrelated directions, one antioxidant and one endocrine. No combination trial defines what they do together.

Zinc is structurally required by the zinc-finger domains of steroid hormone receptors and is a cofactor for enzymes in steroid metabolism. Vitex acts on the pituitary end of the same axis. The relationship is mechanistic and has not been examined as a pairing.

Myo-inositol and D-chiro-inositol act as second messengers downstream of the insulin receptor and in FSH signalling in the ovary. Vitex acts higher up, on hypothalamic and pituitary output. Formulas aimed at cycle regularity combine them because the two sit at different points of the same axis.

Withania affects the hypothalamic-pituitary-adrenal axis and cortisol output in human trials, measured as a hormonal marker. Vitex acts on the hypothalamic-pituitary-gonadal axis. Both touch pituitary output, so combining them in a formula is deliberate and the interaction is at the level of the axis rather than a single receptor.

Rhodiola is used for perceived stress and fatigue and affects monoamine handling. Vitex depends on dopaminergic signalling at the pituitary lactotroph, so a second monoamine-active botanical in the same formula is not neutral. The direction of any combined effect has not been measured.

Glycyrrhizin inhibits 11-beta-hydroxysteroid dehydrogenase type 2, which changes cortisol handling and can raise blood pressure and lower potassium at sustained intake. It also has documented effects on sex hormone measurements. Putting it alongside vitex means two endocrine-active botanicals in one formula, which warrants attention rather than being assumed complementary.

Dandelion leaf and root have a traditional diuretic reputation and appear in formulas aimed at cyclical bloating. Vitex contributes nothing to fluid handling. The pairing is a formulation convention aimed at a different part of the same complaint set.

Silymarin is used for hepatic support, and the liver is where steroid hormones are conjugated and cleared. Formulas pair a hepatic botanical with vitex on that reasoning. The link is a plausible route rather than a measured interaction.

Calcium D-glucarate releases D-glucaro-1,4-lactone in the gut, which inhibits bacterial beta-glucuronidase and reduces deconjugation of glucuronidated steroids in the intestinal lumen. That keeps more conjugated hormone on the excretion path. Vitex acts on secretion, so the two sit at opposite ends of the same hormonal cycle.

DIM, formed from indole-3-carbinol in the stomach, induces CYP1A-mediated hydroxylation and shifts the ratio of oestrogen metabolites, which is a measurable metabolite marker. Vitex acts on pituitary prolactin output rather than on hepatic metabolism. Formulas combine them to cover secretion and clearance in the same product.

Cinnamon appears in cycle-support formulas for its effects on insulin signalling and its traditional use for cramping. Vitex has no metabolic action of that kind. The combination is convention with two unrelated rationales.

Regular menstrual blood loss is the largest ongoing iron drain in women of reproductive age, which is why iron sits in formulas aimed at that population. Vitex does not affect iron absorption or handling in either direction. The two coexist in a product for population reasons rather than a mechanism.

EPA and DHA compete with arachidonic acid for cyclooxygenase and lipoxygenase, shifting eicosanoid production toward less inflammatory series. Prostaglandin production in the endometrium is what drives uterine contraction during menstruation. Vitex acts on the hormonal side, which makes the two rationales non-overlapping.

Vitamin D receptors are present in ovarian and endometrial tissue, and vitamin D governs the calcium absorption step that calcium supplementation depends on. Cycle-support formulas therefore tend to carry vitamin D wherever they carry calcium. Vitex works through a separate endocrine route.

Tyrosine is the substrate for tyrosine hydroxylase and then for dopamine synthesis. Vitex diterpenes act as agonists at pituitary dopamine D2 receptors, which is the receptor end of the same system. Supplying precursor and stimulating the receptor are different interventions and no work has tested them together.